The Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease (TROFEO) trial showed that subjects taking febuxostat achieved more rapid reduction in SUA and required fewer dose adjustments compare to topiroxostat (Sezai et al., 2017) through greater XOR inhibition. This evidence concerns the gene XDH and cardiovascular disorder.